Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMG2YBD)

• Drug Name: Trifluridine Drug Info
• Synonyms: Fluridine; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluridina; Trifluridinum; Virophta; Viroptic; Trifluorothymine deoxyriboside; CF3dUrd; F3DThd; F3T; F3TDR; HS-0007; Trifluridina [INN-Spanish]; Trifluridine [USAN:INN]; Trifluridinum [INN-Latin]; Viroptic (TN); Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Alpha,alpha,alpha-Trifluorothymidine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine
• Therapeutic Class: Antiviral Agents
• Cross-matching ID:
  PubChem CID: 6256
  ChEBI ID: CHEMBL1129
  CAS Number: CAS 70-00-8
  TTD Drug ID: D05RHI
  VARIDT Drug ID: DR00096
  INTEDE Drug ID: DR1643

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.48	0.00e+0	63/73 (86.3%)	CDKN1A;SFN;DDB2;...
Influenza A	2.29	0.00e+0	156/172 (90.7%)	MX1;OAS3;FAS;...
Graft-versus-host disease	2.13	0.00e+0	32/42 (76.19%)	FAS;HLA-DPA1;HLA-B;...
Epstein-Barr virus infection	2.04	0.00e+0	189/202 (93.56%)	CDKN1A;ISG15;OAS3;...
Viral myocarditis	2.01	0.00e+0	53/60 (88.33%)	HLA-DPA1;HLA-B;HLA-F;...
Herpes simplex virus 1 infection	1.97	0.00e+0	165/498 (33.13%)	OAS3;FAS;OAS1;...
Small cell lung cancer	1.96	0.00e+0	90/92 (97.83%)	CDKN1A;DDB2;LAMB3;...
Melanoma	1.95	3.03e-3	68/72 (94.44%)	CDKN1A;DDB2;PDGFA;...
Hepatitis C	1.92	4.04e-3	139/157 (88.54%)	CDKN1A;IFIT1;MX1;...
Measles	1.91	3.64e-3	133/139 (95.68%)	MX1;OAS3;FAS;...
Dilated cardiomyopathy	1.90	3.31e-3	86/96 (89.58%)	GNAS;ITGB4;DES;...
Pancreatic cancer	1.87	8.09e-3	75/76 (98.68%)	CDKN1A;DDB2;TGFA;...
Protein digestion and absorption	1.86	8.40e-3	78/103 (75.73%)	COL15A1;ATP1B1;COL6A2;...
Glioma	1.85	7.80e-3	67/75 (89.33%)	CDKN1A;DDB2;PDGFA;...
Type I diabetes mellitus	1.85	7.28e-3	38/43 (88.37%)	FAS;HLA-DPA1;HLA-B;...
Human papillomavirus infection	1.84	7.58e-3	284/331 (85.8%)	CDKN1A;ISG15;MX1;...
Hypertrophic cardiomyopathy	1.81	9.99e-3	81/90 (90%)	ITGB4;DES;TNNC1;...
Central carbon metabolism in cancer	1.81	9.44e-3	67/70 (95.71%)	PFKL;MET;SLC7A5;...
Allograft rejection	1.81	8.94e-3	32/38 (84.21%)	FAS;HLA-DPA1;HLA-B;...
Glutathione metabolism	1.78	1.40e-2	43/57 (75.44%)	GPX3;RRM2;GSTM3;...
DNA replication	1.78	1.33e-2	34/36 (94.44%)	LIG1;FEN1;POLD4;...
Prostate cancer	1.77	1.32e-2	93/97 (95.88%)	CDKN1A;PDGFA;TGFA;...
ECM-receptor interaction	1.77	1.27e-2	80/88 (90.91%)	ITGB4;LAMB3;LAMC2;...
Focal adhesion	1.77	1.36e-2	180/201 (89.55%)	ITGB4;PDGFA;MET;...
Notch signaling pathway	1.75	1.60e-2	49/59 (83.05%)	NOTCH1;CTBP2;DVL1;...
Basal cell carcinoma	1.74	1.82e-2	41/63 (65.08%)	CDKN1A;DDB2;GADD45A;...
Autoimmune thyroid disease	1.70	2.47e-2	46/53 (86.79%)	FAS;HLA-DPA1;HLA-B;...
Pentose phosphate pathway	1.70	2.38e-2	25/30 (83.33%)	PFKL;TKTL1;G6PD;...
Galactose metabolism	1.67	3.35e-2	26/31 (83.87%)	PFKL;AKR1B1;GALE;...
Thyroid cancer	1.67	3.28e-2	36/37 (97.3%)	CDKN1A;DDB2;GADD45A;...
Nicotine addiction	-1.72	4.05e-2	32/40 (80%)	GABRB3;GRIN2B;GABRA3;...
RNA transport	-1.82	1.84e-2	128/186 (68.82%)	NUP58;RPP30;RANBP2;...
Aminoacyl-tRNA biosynthesis	-1.89	1.31e-2	15/66 (22.73%)	FARS2;LARS2;DARS2;...
Spliceosome	-2.18	2.19e-3	101/150 (67.33%)	SF3B1;THOC2;SNRNP200;...
Ribosome biogenesis in eukaryotes	-2.20	0.00e+0	52/108 (48.15%)	MDN1;MPHOSPH10;IMP3;...
Ribosome	-2.36	0.00e+0	113/158 (71.52%)	RPS3;RPL19;MRPS10;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Fibrocystic breast disease

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A (Parent)	CVCL_0598	Homo sapiens	1.11uM - 10uM	3H, 6H, 12H, 24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Fibroblast

Nasopharyngeal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
FIBRNPC	CVCL_UK07	Homo sapiens	10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼